Vor Biopharma (VOR) Net Cash Flow (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Net Cash Flow of -$226.6 million for Q1 2026, down 610.34% year-over-year from $44.4 million in Q1 2025, and down 196.01% quarter-over-quarter from $236.0 million in Q4 2025.
Vor Biopharma (VOR) Net Cash Flow (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Net Cash Flow for 7 consecutive years, with -$226.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 610.34% year-over-year to -$226.6 million; the TTM figure through Mar 2026 stood at $117.6 million (up 2213.22% YoY), while the FY2025 annual figure was $312.3 million, up 517.31% from the prior year.
- Net Cash Flow declined to -$226.6 million in Q1 2026 per VOR's latest filing, from $236.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $236.0 million in Q4 2025 and bottomed at -$226.6 million in Q1 2026.
- Historically, Net Cash Flow has averaged $2.8 million across 5 years, with a median of -$10.2 million in 2023.
- Annual changes were most pronounced in 2025 — Net Cash Flow soared 709.66% — and 2026, when it slumped 610.34%.
- Vor Biopharma's Net Cash Flow stood at -$3.1 million in 2022, then sank by 337.87% to -$13.7 million in 2023, then surged by 313.31% to $29.2 million in 2024, then jumped by 709.66% to $236.0 million in 2025, then tumbled by 196.01% to -$226.6 million in 2026.
- Business Quant data shows VOR's Net Cash Flow at -$226.6 million in Q1 2026, $236.0 million in Q4 2025, and -$32.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | -62.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.02 Mn |
| Jun 30, 2026 | -62.02 Mn |
| Mar 31, 2026 | -226.61 Mn |
| Mar 31, 2026 | -226.61 Mn |
| Dec 31, 2025 | 236.02 Mn |
| Dec 31, 2025 | 236.02 Mn |
| Sep 30, 2025 | -32.36 Mn |
| Sep 30, 2025 | -32.36 Mn |
| Jun 30, 2025 | 140.53 Mn |
| Jun 30, 2025 | 140.53 Mn |
| Mar 31, 2025 | -31.90 Mn |
| Mar 31, 2025 | -31.90 Mn |
| Dec 31, 2024 | 29.15 Mn |
| Dec 31, 2024 | 29.15 Mn |
| Sep 30, 2024 | -23.28 Mn |
| Sep 30, 2024 | -23.28 Mn |
| Jun 30, 2024 | 31.11 Mn |
| Jun 30, 2024 | 31.11 Mn |
| Mar 31, 2024 | 13.60 Mn |
| Mar 31, 2024 | 13.60 Mn |